480 related articles for article (PubMed ID: 28418292)
1. Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection.
Collins MH; McGowan E; Jadi R; Young E; Lopez CA; Baric RS; Lazear HM; de Silva AM
Emerg Infect Dis; 2017 May; 23(5):773-781. PubMed ID: 28418292
[TBL] [Abstract][Full Text] [Related]
2. Zika convalescent macaques display delayed induction of anamnestic cross-neutralizing antibody responses after dengue infection.
Valiant WG; Huang YS; Vanlandingham DL; Higgs S; Lewis MG; Mattapallil JJ
Emerg Microbes Infect; 2018 Jul; 7(1):130. PubMed ID: 30006514
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Analysis of Antibody Cross-neutralization Following Zika Virus and Dengue Virus Infection in Asia and the Americas.
Montoya M; Collins M; Dejnirattisai W; Katzelnick LC; Puerta-Guardo H; Jadi R; Schildhauer S; Supasa P; Vasanawathana S; Malasit P; Mongkolsapaya J; de Silva AD; Tissera H; Balmaseda A; Screaton G; de Silva AM; Harris E
J Infect Dis; 2018 Jul; 218(4):536-545. PubMed ID: 29618091
[TBL] [Abstract][Full Text] [Related]
4. Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus.
Swanstrom JA; Plante JA; Plante KS; Young EF; McGowan E; Gallichotte EN; Widman DG; Heise MT; de Silva AM; Baric RS
mBio; 2016 Jul; 7(4):. PubMed ID: 27435464
[TBL] [Abstract][Full Text] [Related]
5. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.
Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W
Front Immunol; 2018; 9():597. PubMed ID: 29740424
[TBL] [Abstract][Full Text] [Related]
6. Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice.
Fowler AM; Tang WW; Young MP; Mamidi A; Viramontes KM; McCauley MD; Carlin AF; Schooley RT; Swanstrom J; Baric RS; Govero J; Diamond MS; Shresta S
Cell Host Microbe; 2018 Nov; 24(5):743-750.e5. PubMed ID: 30439343
[TBL] [Abstract][Full Text] [Related]
7. Cross-Reaction, Enhancement, and Neutralization Activity of Dengue Virus Antibodies against Zika Virus: A Study in the Mexican Population.
Montecillo-Aguado MR; Montes-Gómez AE; García-Cordero J; Corzo-Gómez J; Vivanco-Cid H; Mellado-Sánchez G; Muñoz-Medina JE; Gutiérrez-Castañeda B; Santos-Argumedo L; González-Bonilla C; Cedillo-Barrón L
J Immunol Res; 2019; 2019():7239347. PubMed ID: 31565661
[TBL] [Abstract][Full Text] [Related]
8. Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies.
Tsai WY; Durbin A; Tsai JJ; Hsieh SC; Whitehead S; Wang WK
J Virol; 2015 Jul; 89(14):7348-62. PubMed ID: 25972550
[TBL] [Abstract][Full Text] [Related]
9. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
[TBL] [Abstract][Full Text] [Related]
10. Seroprevalence of Flavivirus Neutralizing Antibodies in Thailand by High-Throughput Neutralization Assay: Endemic Circulation of Zika Virus before 2012.
Yamanaka A; Matsuda M; Okabayashi T; Pitaksajjakul P; Ramasoota P; Saito K; Fukasawa M; Hanada K; Matsuura T; Muramatsu M; Shioda T; Suzuki R
mSphere; 2021 Aug; 6(4):e0033921. PubMed ID: 34259560
[TBL] [Abstract][Full Text] [Related]
11. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Anti-Dengue and Anti-Zika IgG on a Plasmonic Gold Platform with Neutralization Testing.
Rojas A; Natrajan MS; Weber J; Cardozo F; Cantero C; Ananta JS; Kost J; Tang M; López S; Bernal C; Guillén Y; Mendoza L; Páez M; Pinsky BA; Waggoner JJ
Am J Trop Med Hyg; 2021 Mar; 104(5):1729-1733. PubMed ID: 33782214
[TBL] [Abstract][Full Text] [Related]
13. Development of Envelope Protein Antigens To Serologically Differentiate Zika Virus Infection from Dengue Virus Infection.
Premkumar L; Collins M; Graham S; Liou GA; Lopez CA; Jadi R; Balmaseda A; Brackbill JA; Dietze R; Camacho E; De Silva AD; Giuberti C; Dos Reis HL; Singh T; Heimsath H; Weiskopf D; Sette A; Osorio JE; Permar SR; Miley MJ; Lazear HM; Harris E; de Silva AM
J Clin Microbiol; 2018 Mar; 56(3):. PubMed ID: 29263206
[TBL] [Abstract][Full Text] [Related]
14. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
[TBL] [Abstract][Full Text] [Related]
15. Primary and Secondary Dengue Virus Infections Elicit Similar Memory B-Cell Responses, but Breadth to Other Serotypes and Cross-Reactivity to Zika Virus Is Higher in Secondary Dengue.
Andrade P; Narvekar P; Montoya M; Michlmayr D; Balmaseda A; Coloma J; Harris E
J Infect Dis; 2020 Jul; 222(4):590-600. PubMed ID: 32193549
[TBL] [Abstract][Full Text] [Related]
16. Prior dengue virus serotype 3 infection modulates subsequent plasmablast responses to Zika virus infection in rhesus macaques.
Singh T; Miller IG; Venkatayogi S; Webster H; Heimsath HJ; Eudailey JA; Dudley DM; Kumar A; Mangan RJ; Thein A; Aliota MT; Newman CM; Mohns MS; Breitbach ME; Berry M; Friedrich TC; Wiehe K; O'Connor DH; Permar SR
mBio; 2024 Mar; 15(3):e0316023. PubMed ID: 38349142
[TBL] [Abstract][Full Text] [Related]
17. Identification of Anti-Premembrane Antibody as a Serocomplex-Specific Marker To Discriminate Zika, Dengue, and West Nile Virus Infections.
Hsieh SC; Tsai WY; Tsai JJ; Stone M; Simmons G; Busch MP; Lanteri M; Stramer SL; Balmaseda A; Harris E; Wang WK
J Virol; 2021 Sep; 95(19):e0061921. PubMed ID: 34232731
[TBL] [Abstract][Full Text] [Related]
18. Dengue immune sera enhance Zika virus infection in human peripheral blood monocytes through Fc gamma receptors.
Li M; Zhao L; Zhang C; Wang X; Hong W; Sun J; Liu R; Yu L; Wang J; Zhang F; Jin X
PLoS One; 2018; 13(7):e0200478. PubMed ID: 30044839
[TBL] [Abstract][Full Text] [Related]
19. Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development.
Elong Ngono A; Shresta S
Front Immunol; 2019; 10():1316. PubMed ID: 31244855
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of IgG Depletion in a Neutralization Assay Facilitates Differential Diagnosis of Zika and Dengue in Secondary Flavivirus Infection Cases.
Calvert AE; Boroughs KL; Laven J; Stovall JL; Luy BE; Kosoy OI; Huang CY
J Clin Microbiol; 2018 Jun; 56(6):. PubMed ID: 29618505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
